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Abstract: Multifunctional cyclopentadiene ligands and their rhenium 
and 99mTc complexes were prepared along a versatile synthetic route. 
The properties of these Cp-ligands can be tuned on demand, either 
during their synthesis (variation of R1) or through post-synthetic 
functionalization with two equal or different vectors (V1 and V2). 
Variation of these groups enables a combinatorial approach in the 
synthesis of bioorganometallic complexes. This is demonstrated by 
the preparation of Cp-ligands containing both electron-donating and 
withdrawing groups at the R1 position and their subsequent homo- or 
hetero-functionalization with biovector models (benzylamine and 
phenylalanine) under standard amide bond formation conditions. All 
ligands can be coordinated to the fac-[Re(CO)3]+ and fac-
[99mTc(CO)3]+ core, leading to tetra-functional complexes via straight-
forward and functional-group tolerant procedures. Importantly, the 
99mTc complexes were prepared in one-step, in 30 min and under 
aqueous conditions from generator eluted [99mTcO4]-. 
Introduction 
The combination of organometallic complexes with biologically active, 
organic molecules or fragments has become an intensely researched 
field in medicinal inorganic chemistry. These bioorganometallic 
complexes play a distinct role and benefit from a series of properties 
different from coordination compounds.[1] They may form integrated 
substructures in pharmaceutically active lead compounds such as in 
the tamoxifen/ferrocifen couple,[2] exert cytotoxicity through metal-
mediated interactions with proteins or nucleic acids as in the case of 
the [(η6-arene)Ru]2+ fragment[3] or form de novo parts as e.g. in 
bioorganometallic kinase inhibitors.[4] Ferrocene (Fc) represents one 
of the main building blocks in this field and the cyclopentadienyl (Cp) 
ligand plays an important role in all Fc-based bioorganometallic 
concepts. The majority of Cp-based bioorganometallic complexes 
comprises one single additional functionality, a pendent targeting 
moiety, a cytotoxic or otherwise biologically active agent. Cp-ligands 
are not only found in ferrocene but also in Re/99mTc piano-stool type 
complexes. We recently reported two examples in which such 
Re/99mTc complexes were conjugated to carbonic anhydrase inhibitors 
or cytotoxic doxorubicin.[5] Since biological activities of group 7 piano-
stool complexes are rather overall structure- than metal-based, a 
combination of rhenium and 99mTc complexes is a complementary 
strategy in theranostics; the rhenium complex for therapy and its 99mTc 
homologue for imaging. This combination is interesting since 99mTc is 
still core in Single Photon Emission Tomography (SPECT)[6] due to its 
half-life (t1/2 = 6.02 h), decay characteristics and, of growing 
importance, its price.[7] Since 2001 only a limited number of new 99mTc 
imaging agents have been introduced into clinical routine.[8] This 
mirrors the challenges encountered when aiming at introducing a well-
defined transition metal complex into a targeting molecule in 
quantitative yields and in one-step as required for routine clinical 
application.[9] The preparation of fac-[99mTc(OH2)3(CO)3]+ was a step in 
this direction and a wide variety of complexes based on the fac-
[99mTc(CO)3]+ core have been explored ever since.[5a, 10] Recently, a 
PSMA targeting biovector coupled to the tricarbonyl core made it into 
phase III clinical trials.[11] The general concept of targeted radiotracers 
is the conjugation of a receptor-binding molecule with a ligand for 
coordination to the respective metal centre or complex fragment, also 
referred to as the bifunctional ligand or pendent approach. 
 
 
Figure 1.  Overview of the different poly-modalities accessible with the new 
multifunctional cyclopentadienyl ligands. 
 
Current pharmaceutical research aims at combining multiple 
modalities such as targeting and cytotoxicity, in one single molecule. 
This approach has not yet found the consideration it deserves in 
bioorganometallic chemistry, probably since the modalities are ideally 
conjugated to one single ligand. With respect to imaging, the concept 
is further affected by the fact that a multi-modality 99mTc complex must 
be synthesized in one single step from [99mTcO4]- and in water.  
Cp-ligands represent a scaffold to which multiple functionalities can 
be bound according to elaborate organic synthetic strategies. In 
addition, Cp is a small and strongly binding ligand with a low molecular 
weight. After coordination to the fac-[M(CO)3]+ core, the complexes 
are highly inert and of zero charge. Our group reported a one-pot 
synthesis of singly functionalized {(η5-C5H5)99mTc} complexes in water 
under moderate heating.[12] By derivatizing di-cyclopentadiene 
“Thiele’s acid” through amid bond formation, chemically stable and 
functionalized Cp-precursors and complexes of the type [(η5-
C5H4R)99mTc(CO)3] became accessible.[5a, 13]   
 
The bifunctional ligand approach, with or without Cp, does not 
immediately comprise the option of combining multiple, different or 
equal, targeting vectors. Multimeric molecular imaging agents would 
offer many new opportunities such as targeting of different sites, 
 
enhancing binding affinities and/or addition of a cytotoxic payload. 
Only a few multimeric molecular 99mTc imaging agents have been 
reported thus far, mainly by Liu et al. on integrin αvβ3 targeting 
multimeric cyclic-RGD peptide oligomers.[14] For Cp, all approaches 
described above are synthetically incompatible with multi-
functionalization as required for multimeric targeting agents.  
We reported recently the synthesis of water soluble Re/99mTc 
complexes with a Cp-ligand for coordination to the {99mTc(CO)3}+ core 
and two carboxylato groups in 1,2-position for potential conjugation to 
two biomolecules.[15] In this study, we extend the flexibility of the multi-
functional Cp-approach to a C5H3R1R2R3-type scaffold, which can be 
mono- (Figure 1A) or homo (Figure 1B) and hetero (Figure 1B) bi-
functionalized with respect to targeting molecules or other biovectors. 
The choice of biovectors or molecular functionalities attached to the 
central Cp-core is highly flexible which allows for a systematic 
exploration of new imaging compounds. The ligands as such do not 
undergo Diels-Alder dimerization and are water and air-stable at room 
temperature and up to 220 °C. Mono-, homo- and hetero-
functionalization of the ligand is shown with model vectors on both the 
free ligand and the “cold” rhenium complexes. The corresponding 
99mTc complexes were prepared in a one-pot reaction from [99mTcO4]- 
and in high radiochemical yields. Altogether, we present a ligand 
platform that allows for the synthesis of tetra-functional Re/99mTc 
complexes but also for other elements. Combinatorial variation of all 
pendent groups will lead to a wide variety of structurally different but 
functionally identical matched-pair complexes. 
 
Results and Discussion 
Design of Cp-Ligands. The syntheses of the multi-functional 
cyclopentadiene ligands in this study as shown in Figure 1 are based 
on a procedure by Hatanaka et al.[16]. A variety of triphenyl-
phosphonium salts with different substituents R1 react with α-bromo-
ketones under mild conditions to form triply substituted Cp’s in good 
yields. The most general concept towards such multi-functionalized 
Cp's is shown in Scheme 1 (top). The carboxylate group directly 
attached to the Cp-ring (R4, green in Scheme 1) and the terminal 
carboxylate in R2 (blue) allow for later conjugation of two equal or 
different biological functions V1 and V2. This synthetic approach thus 
enables a versatile alteration of three functionalities; R1 for guiding the 
chemical properties and the two carboxylate groups for conjugation of 
bioactive functionalities (Scheme 1, A and B). The original literature 
also highlights the possibility to vary R2 and to introduce further 
functionalities at R3, while modifications of R4 and R5 are also 
conceivable. 
 
Scheme 1. General synthesis of multifunctional Cp-ligands (top) and the 
synthetic strategy pursued in this study (bottom): A) variation of R1 to modify the 
chemical properties of the Cp. B) variation of the conjugated vectors (V1, V2) to 
modify biological properties of the Cp. 
 
We did not alter all these positions on the central cyclopentadiene 
scaffold but choose ethyl 5-bromo-4-oxopentanoate (0.1 Scheme 2) 
as the standard α-bromo-ketone for the bi-functionalization, keeping 
R2 thereby constant with the option of conjugating a vector V2 to this 
position. 
 
The (CH2)2-spacer in R2 was introduced in this building block design 
to reduce interference of the terminal ester group with the reactivity of 
the α-ketone. Furthermore, this spacer suppresses the undesired 
rearrangement of the Cp-double bond in the final ligand, as previously 
observed in our group in mono-functional Cp’s with one CH2 group 
between Cp and the ester group. The ester group on the 
phosphonium building block (R4, green in Scheme 1) was also kept 
constant and will enable the conjugation of a 2nd bioactive moiety V1 
to the Cp-scaffold after cyclization. In its essence, the approach 
towards multi-functionalized Cp derivatives focuses on the building 
block A in Scheme 1, prepared from ethyl 5-bromo-4-oxopentanoate 
and phosphonium salts with a methyl (1a), a phenyl (4a) and a 
methoxy (6a) group as R1, red in Scheme 1 to show that both electron 
donating and withdrawing groups can equally be bound to the Cp-ring. 
Introduction of V1 and V2 will lead to the trifunctional Cp derivatives as 
shown with B in Scheme 1. Since metal complexes with Cp-ligands of 
type A have already been reported for iron[17], ruthenium[18], cobalt[19] 
and rhodium[17a, 20], we suggest that Cp derivatives of type B can 
equally be applied to other metal centres.  
 
Scheme 2.  Synthetic route to the Cp-ligands 1a, 4a, 6a. Reaction conditions: 
a) Br2, MeOH, 0 °C, 24 h, 23%. b) cat. H2SO4, EtOH, reflux, overnight, 87%. c) 
NBS, cat. AIBN, MeOAc, MW; 110 °C, 15 min (1.2, 83%); 110 °C 12 min (4.2, 
97%); 85 °C, 30 s (6.2, 73%). d) PPh3, dry toluene, 25 °C, 24 h (1.3, 84%; 4.3, 
65%; 6.3, 54%). e) 0.1, DCM/sat. NaHCO3, 25 °C, 48 h (1a, 66%; 4a, 27%; 6a, 
23%). f) Trimethoxymethane, H2SO4, 25 °C, 25 h, 82%.  
Synthesis and Characterization. The ligands 1a, 4a and 6a 
represent the cores of the later trifunctional Cp-systems. These 
precursors were synthesized following the reported procedure with 
minor changes to improve yields and isolations (see Supplementary 
Information for details).[16] Notably, the radical brominations of 1.1, 4.1, 
and 6.1 (Scheme 2) to yield 1.2, 4.2 and 6.2 were carried out under 
microwave conditions in less than 15 min (30 s at 85 °C for 6.1). The 
harmful solvent CCl4 could be replaced by methylacetate without loss 
of performance. Subsequent reactions with triphenyl-phosphine and 
cyclizations with 5-bromo-4-oxopentanoate lead straight to the Cp-
ligands 1a, 4a and 6a in moderate to good yields and in up to gram 
quantities after purification by silica column chromatography. 
 
Scheme 3. Synthetic route towards bis-homo functionalized Re and 99mTc 
complexes. Reaction conditions: a) Re2CO10, o-xylene, MW, 220 °C, 15 min 
(1b, 76%; 4b, 83%; 6b, 44%). b) NaOH, MeOH, MW, 120 °C, 15 min (2b, 68%; 
5b, 92%; 7b, 48%). c) benzylamine, HOBt, EDC, DMF, 25 °C, 24 h, (3a, 38%; 
3b, 16%). d) [TcO4]-, sodium boranocarbonate, sodium tartrate, sodium 
tetraborate, H2O, MW, 120 °C, 30 min. 
 
The rhenium complexes 1b, 4b and 6b with all three Cp-derivatives 
were obtained by refluxing the respective ligand 1a, 4a and 6a with 
Re2CO10 for multiple days in o-xylene (Scheme 3). Under microwave 
conditions, the reaction solutions were heated to 220 °C and the 
reaction time reduced to 15 min (as described in the supplementary 
information) without loss of yields. For 1b, UPLC analysis indicated 
complete consumption of starting material and sufficiently pure 
complex could be obtained without further purification. Complexes 4b 
and 6b were purified by column chromatography on silica. Ester 
hydrolysis to 2b, 5b and 7b was achieved under basic conditions by 
either refluxing overnight under basic conditions or by microwave 
heating at 120 °C for 15 min. To demonstrate the possibility of bis-
homo functionalization, ligand 2a and complex 2b were reacted with 
two equivalents of a model biovector, benzylamine, yielding the 
respective bis-amide compounds 3a and 3b after purification by 
preparative HPLC. Single crystals suitable for X-ray analysis were 
obtained for 2b and 3b (Figure 2). 
 
 
Figure 2. Crystal structures of 2b and 3b. Displacement ellipsoid 
representation. Ellipsoids are drawn at 50% probability. Important bond lengths 
(Å): 2b Re-centroid of Cp: 1.950(2), 3b Re-centroid of Cp: 1.945(3). 
 
Bis-hetero functionalization of the Cp-ligand 1a: To assess the full 
potential of this approach and to open a scope towards two different 
functions V1 and V2, i.e. bis-hetero functionalized Cp-ligands and 
complexes, the individual carboxylato groups must be conjugated 
stepwise to biovectors. We exemplify this strategy with the Cp ligand 
1a, which comprises the methyl group at the R1 position. The first 
mono-functionalization was achieved by hydrolysis of 1a with slightly 
less than one equivalent of NaOH, yielding exclusively 8a (Scheme 
4). One could expect a statistical distribution of hydrolysis at both 
ester functions but the one at the R2 position is obviously more 
susceptible, leaving R4 untouched. Subsequent amide bond formation 
under the previously mentioned conditions gave 9a in good yields. By 
further and carefully tuning the reaction conditions, 9a could 
selectively be hydrolyzed to 10a. Reaction times longer than 5 min 
and pressures over 5 bar usually resulted in decomposition of the 
compound. For subsequent bis-hetero-functionalization, we chose O-
tbutyl-L-phenylalanine to demonstrate that our approach is substrate 
tolerant with the option of extension to e.g. peptides. Along a standard 
peptide bond formation strategy (see ESI), 10a was converted into 
11a, containing two different functionalities on the cyclopentadiene 
ring. 
Bis-hetero functionalization of the rhenium complex 2b: Unlike 
the Cp-ligand 1a itself, selective mono-hydrolysis of 1b (Scheme 3) 
was not possible. Addition of 1 eq. of NaOH and subsequent heating 
gave a statistical mixture of ester-hydrolyzed products. Thus, to 
accomplish the rhenium complex 8b, a direct reaction between the 
mono-acid ligand 8a and Re2CO10 in DMF under microwave 
irradiation was performed. The obtained crude mixture was directly 
reacted under standard peptide coupling conditions to give 9b after 
purification by preparative HPLC (Figure 4). Complex 9b was then 
easily further hydrolyzed and functionalized with O-tbutyl-L-
phenylalanine, yielding 11b after preparative HPLC in 26% yield. The 
tert-butyl protecting group of 11b could be cleaved by treatment with 
TFA in DCM at 80 °C, yielding 12b as a model for the later 99mTc 
complexes. 
 
Scheme 4. Synthetic route towards hetero-functionalized Re and 99mTc 
complexes. Reaction conditions: a) NaOH, MeOH, MW, 120 °C, 15 min. b) 
benzylamine, HOBt, EDC, DMF, 25 °C, 48 h, 69%. c) i) NaOH, MeOH, MW, 120 
°C, 15 min. ii) O-tertbutyl-L-Phenylalanine, HOBt, EDC, DMF, 25 °C, 24 h, (11a, 
26%; 11b, 46%). d) [TcO4]-, sodium boranocarbonate, sodium tartrate, sodium 
tetraborate, H2O, MW, 140 °C, 30 min. e) Re2CO10, DMF, MW, 220 °C, 15 min. 
f) TFA, DCM, MW, 80 °C, 15 min, 80%.  
 
The chiral centre in the attached amino acid together with the chiral 
planarity of the asymmetric Cp-ligand leads to the formation of two 
diastereomers (see Figure SI88). This was confirmed by the 
observation of two sets of NMR signals in both 1H and 13C NMR 
spectra of 11b and 12b (Figures SI83-84). All compounds were fully 
characterized by NMR, HPLC and HR ESI-MS. These synthetic 
results clearly imply that more complex biomolecules can be 
conjugated to both, the free ligand and to the rhenium complexes 
themselves. For rhenium, ligand 8a and complex 8b are key since 
they will allow the consecutive introduction of two different 
functionalities on the ligand (8a) for later labelling with 99mTc (vide 
infra) or on the rhenium complex (8b) for biological evaluation and 
comparison with the 99mTc complex.  
Radiolabelling with 99mTc: It is the common notion that Cp-
systems, capable of binding in aqueous solution to the 
[99mTc(CO)3]+ fragment, have to comprise electron withdrawing 
groups directly on the cyclopentadiene scaffold. This will 
sufficiently acidify the ring to have at least small amounts of the 
ligand deprotonated and therefore prone to coordination. 
Accordingly, most of the approaches towards [(η5-C5H4-
R)99mTc(CO)3] type complexes comprise a carbonyl function 
directly on the Cp ring.[5a, 10c, 13a, 21] First, we radiolabelled the 
underivatized ligands 1a, 4a and 6a which follow this concept of 
acidification and should therefore readily react with the 
[99mTc(OH2)3(CO)3]+ precursor. In a two-step approach, fac-
[99mTc(OH2)3(CO)3]+ was prepared and then reacted with ligands 
1a, 4a and 6a at millimolar concentrations. Along this path, the 
99mTc complexes 2c, 5c and 7c (Scheme 3) could all be obtained 
in high radiochemical yields under alkaline conditions and 
microwave heating at 120 °C for 30 min (see experimental part). 
Having shown that radiolabelling of these ligands with fac-
[99mTc(OH2)3(CO)3]+ was straight-forward, we attempted the 
direct synthesis of the 99mTc complexes (2c, 5c and 7c) directly 
from [TcO4]- in a “one-pot” approach. By mixing all components 
in a single vial and adding directly the [99mTcO4]- generator eluate, 
complexes 2c, 5c and 7c formed quantitatively by an improved 
procedure under microwave conditions in 30 min at 120 °C 
(Figure 3). We emphasize that these are conditions compatible 
with routine applications in clinics.  
 
 
Figure 3. General reaction scheme for the “one-pot” synthesis of 99mTc 
compounds (top). UV- and y-traces of the co-injection of the rhenium 
compounds 2b, 5b and 7b with the 99mTc compounds 2c, 5c and 6c respectively 
(bottom). Differences in retention times are due to detector separation. 
As typical 99mTc concentrations are too low for standard chemical 
characterizations of the formed complexes by e.g. NMR, the accepted 
procedure for their characterizations is HPLC co-injection with the 
“cold” rhenium homologue and comparison of retention times (γ-trace 
for 99mTc, UV-trace for Re). Figure 3 shows the HPLC traces of the 
respective 99mTc complexes as obtained after direct preparations in 
quantitative yields with all three ligands from [99mTcO4]-. Further 
purification was not required. Due to the basic conditions, the ester 
groups hydrolysed during the labelling process, wherefore co-
injections were performed with the di-acid rhenium homologues (2b, 
5b and 7b). The retention times match, corroborating the identity of 
the two homologous complexes with Re and 99mTc. 
 
Figure 4. UV/vis- and γ-traces of the co-injection of the rhenium compounds 
3b and 12b with the 99mTc compounds 3c and 12c respectively. Time 
differences are due to detector separation. 
The Cp compounds 3a (homo-difunctionalized) and 11a (hetero-
difunctionalized) bear two model functionalities V1 and V2 at positions 
R2 and R4 in the basic cyclopentadiene structure, conjugated via an 
amide to the cyclopentadiene ring. These ligands represent the basic 
structure for a combinatorial approach since essentially any two 
amine-bearing biovectors can be added. The labeling of such more 
complex systems in general and 3a and 11a in particular is an 
exemplary step in the preparation of multi-functional molecular 
imaging agents. Accordingly, by following the preparations as 
described above, ligands 3a and 11a could be labelled along the one-
pot procedure directly from [99mTcO4]-, giving the corresponding 99mTc 
complexes 3c and 12c in good yields (Figure 4).  Slightly higher 
temperatures and reaction times were required. As a convenient "side 
effect", the tert-butyl protective group was concertedly cleaved during 
the reaction in case of 11a. Taken together, these results demonstrate 
the possibility to synthesize 99mTc piano-stool type molecular imaging 
agents with structurally complex and multifunctional Cp ligands in one 
step directly from [99mTcO4]- in a straight-forward and efficient way. 
The option of altering V1 and V2 (phenyl-alanine and benzyl-amine in 
our case) opens a path towards further combinations of biologically 
active moieties. 
Conclusions 
We present versatile synthetic routes towards multiply substituted 
cyclopentadiene, which are the basis for the subsequent preparation 
of multifunctional ligands. Both, the physico-chemical (group R1) as 
well as the biological (V1 and V2) properties can be tuned individually 
in the same ligand. We have furthermore shown that these 
cyclopentadiene scaffolds serve as a ligand platform in 
bioorganometallic 99mTc chemistry that allows the introduction of 
multiple modalities in a straightforward way. The ligands as such can 
be prepared separately with functionalities V1 and V2 according to the 
target requirements. The "innocent" group R1 on the Cp scaffold 
influences the physico-chemical properties such as lipo/hydrophilicity 
while leaving the targeting properties untouched. Three 
representative ligands (1a, 3a, 5a) with different R1 groups have been 
synthesized, fully characterized and coordinated to the fac-[Re(CO)3] 
moiety. As a further proof-of-concept, 1a was both bis-homo - and bis-
hetero functionalized with two simple biovector-models. Established 
amide bond formation chemistry for the vector conjugation, ensures 
its applicability to a wide variety of modalities. The combination of 
these ligands with the theranostic pair Re and 99mTc leads to tetra-
functional complexes. Their synthesis is both straightforward, highly 
tolerant to different functionalities and, most importantly, the 99mTc 
homologues are prepared in one step directly from generator eluted 
[99mTcO4]-. We envision that this ligand platform will enable a 
combinatorial approach towards targeted and multimodal 
bioorganometallic complexes. 
Experimental Section 
Materials.  All chemicals were of reagent-grade quality or higher and 
were obtained from commercial suppliers. Solvents were used as 
received or dried over molecular sieves. Sodium boranocarbonate 
was a gift from Mallinckrodt Medical B.V. (The Netherlands). 
Na[99mTcO4] in 0.9% saline was eluted from a 99Mo/99mTc UTK FM 
generator purchased from Mallinckrodt Medical B.V.  
Instrumentation and methods. 1H and 13C-NMR spectra were 
recorded in deuterated solvents on a Bruker DRX 400 (1H: 400 MHz, 
13C: 100.6 MHz) or DRX 500 (1H: 500 MHz 13C: 125.8 MHz) MHz 
spectrometer at 300 K. The chemical shifts, 𝛿𝛿, are reported in ppm 
(parts per million) relative to residual solvent peaks. IR spectra were 
obtained with a PerkinElmer Spectrum Two spectrometer. UPLC-ESI-
MS was performed on a Waters Acquity UPLC System coupled to a 
Bruker HCTTM, using an Acquity UPLC BEH C18 1.7μm (2.1 x 50 mm) 
column. UPLC solvents were formic acid (0.1% in millipore water) 
(solvent A) and acetonitrile UPLC grade (solvent B). The temperature 
was regulated with a Peltier thermostatic system to the specified 
temperatures. High-resolution mass spectrometry (HR-MS) was 
performed on a Thermo DFS double-focusing system (ThermoFisher 
Scientific, Germany). 
Preparative HPLC was performed on a Varian ProStar 320 system, 
using a Dr. Maisch Reprosil C18 100-7 (40 x 250 mm) column (flow 
rate: 40.0 ml/min) or a LiChroCART RP-18e (10 x 250 mm) column. 
HPLC solvents were 0.1% trifluoroacetic acid (solvent A) and 
acetonitrile (solvent B), HPLC grade. Microwave reactions were 
performed using a Biotage Initiator+ Robot Eight or Anton Paar (AP) 
Monowave 200 instrument. Analytical HPLC was performed on a 
Merck Hitachi L7000 system, equipped with a L-7400 UV-detector and 
an in-line radio-detector Berthold FlowStar LB513, using an analytical 
Macherey-Nagel Nucleosil C18 5 μm (4.6 × 250 mm) column. HPLC 
solvents were 0.1% trifluoroacetic acid (solvent A) and acetonitrile, 
HPLC grade (solvent B). Analytical UPLC was performed on a VWR 
Hitachi Chrommaster Ultra, using an Acquity UPLC BEH C18 1.7μm 
(2.1 x 50 mm) column. UPLC solvents were trifluoroacetic acid (0.1% 
in millipore water) (solvent A) and acetonitrile UPLC grade (solvent 
 
B). HPLC and UPLC gradients are given in the Supporting 
Information. 
 
Synthesis of Cp-ligands and Re-complexes. 
 
General Procedure for the synthesis of complexes 1b, 4b and 6b 
A solution of the complex (1 equiv.) and Re2(CO)10 (0.52 equiv) in o-
Xylene (2 ml) in a Anton Paar microwave vial (10 ml) equipped with a 
stirring bar was heated to 220 °C for 15 min (Careful, toxic CO gas is 
released during the reaction, take appropriate precautions). The 
solvent was evaporated in vacuo, yielding pure complex after column 
chromatography on silica gel (no further purification was necessary 
for complex 1b). 
 
General procedure for the synthesis of complexes 2b, 5b and 7b 
A solution of the complex (1 equiv) in MeOH (1 ml) and 1 M NaOH 
(0.5 ml) in a Anton Paar microwave vial (10 ml) was heated by 
microwave to 120 °C for 15 min. The crude was diluted with 1 M HCl 
(20 ml) and washed with DCM twice (2 x 20 ml). The combined 
organic phase was washed once with water (20 ml) dried over MgSO4 
and the solvent removed in vacuo yielding pure complex.  
 
2a. 1a (31 mg, 0.13 mmol) was dissolved in MeOH (1 ml) in a Anton 
Paar microwave vial (10 ml) equipped with a stirring bar. 1 M NaOH 
was added (0.4 ml) and the solution was heated by microwave to 120 
°C for 15 min. UPLC measurement showed complete consumption of 
the starting material. The reaction solution was diluted with H2O (5 ml) 
and neutralized to pH = 3 by dropwise addition of 1 M HCl. 2a was 
obtained by evaporating the solvent in vacuo and was used without 
further purification. UPLC (gradient U1): RT = 1.91 min. 
 
3a. 2a (48 mg, 0.21 mmol) was dissolved in DMF (2 ml). Benzylamine 
(0.53 ml, 0.49 mmol) and HOBt (66 mg, 0.49 mmol) were added under 
stirring. After 5 min, EDC (93 mg, 0.49 mmol) and DIPEA (0.170 ml, 
0.98 mmol) were added and the solution was stirred at room 
temperature for 48 h. The solvent was removed in vacuo and the 
crude was purified by preparative HPLC (Method A) and 3a was 
obtained as a yellowish powder (30 mg, 0.08 mm, 38 %). UPLC 
(gradient U1): RT = 2.65 min.  1H NMR (400 MHz, CDCl3): δ (ppm) 
2.25 (m, 3H), 2.49 (m, 2H), 2.72 – 2.75 (m, 2H), 3.25 – 3.26 (m, 2H), 
4.34 (s, 2H), 4.46 (s, 2H), 6.11 (s, 1H), 7.19 – 7.30 (m, 10H). 13C NMR 
(125 MHz, CDCl3): δ (ppm) 15.39, 27.54, 36.51, 43.78, 44.05, 44.69, 
127.99, 128.18, 128.40, 128.48, 129.45, 129.52, 130.64, 133.87, 
139.95, 140.68, 152.27, 152.95, 168.03, 174.92. HR-ESI mass 
spectrum (MeOH): found 375.20669; calcd. for [C24H27O2N2] 
375.20670. 
 
3b. 2b (47 mg, 0.1 mmol) was dissolved in DMF (5 ml). Benzylamine 
(0.023 ml, 0.21 mmol) and HOBt (29 mg, 0.21 mmol) were added 
under stirring. After 5 min, EDC (41 mg, 0.21 mmol) and DIPEA (0.073 
ml, 0.42 mmol) were added and the solution was stirred for 24 h. The 
solvent was removed in vacuo and the crude was purified by 
preparative HPLC (Method A) and 3a was obtained as a pale yellow 
powder (10 mg, 0.016 mmol, 16 %). Single crystals were obtained by 
slow evaporation of a MeOH solution. UPLC (gradient U1): RT = 3.20 
min. 1H NMR (400 MHz, CDCl3): δ (ppm) 2.45 (t, 3J = 7.2 Hz, 2H), 2.48 
(s, 3H), 2.64 – 2.78 (m, 2H), 4.32 – 4.51 (m, 4H), 5.40 (d, J3 = 2.0 Hz, 
1H), 5.97 (d, J3 = 2.0 Hz, 1H) 7.21 – 7.30 (m, 10H) 8.40 – 8.44 (m, 
2H). 13C NMR (125 MHz, CDCl3): δ (ppm) 14.17, 25.30, 38.73, 43.98, 
44.12, 49.00, 84.82, 86.78, 90.93, 108.57, 111.42, 128.14, 128.26, 
128.38, 128.56, 129.50, 129.57, 139.85, 139.99, 166.28, 173.85, 
195.29. IR bands (Golden Gate, cm-1): 2017, 1906. HR-ESI mass 
spectrum (MeOH): found 645.13941; calcd. for [C27H26O5N2Re+H+] 
645.13937. 
 
8a. 1a (38 mg, 0.16 mmol) was dissolved in MeOH (1 ml) in a Anton 
Paar microwave vial (10 ml) equipped with a stirring bar. 1 M NaOH 
was added (0.150 ml, 0.150 mmol) and the solution was heated to 
120 °C for 15 min. UPLC measurement showed complete 
consumption of the starting material. The reaction solution was diluted 
with H2O (5 ml) and neutralized to pH = 3 by dropwise addition of 1 M 
HCl. 8a was obtained by evaporating the solvent in vacuo and was 
used without further purification. UPLC (gradient U1): RT = 2.49 min. 
 
9a. 8a (59 mg, 0.26 mmol) was dissolved in DMF (4 ml). Benzylamine 
(0.031 ml, 0.29 mmol) and HOBt (39 mg, 0.29 mmol) were added 
under stirring. After 5 min, EDC (55 mg, 0.29 mmol) and DIPEA (0.100 
ml, 0.57 mmol) were added and the solution was stirred for 48 h. The 
solvent was removed in vacuo and the crude was purified by 
preparative HPLC (Method A) and 9a was obtained as a yellow oil (57 
mg, 0.18 mmol, 69 %). UPLC (gradient U1): RT = 2.76 min. 1H NMR 
(400 MHz, CDCl3): δ (ppm): 1.29 (t, J3 = 7.1 Hz, 3H), 2.27 (t, J3 = 2.3 
Hz, 3H), 2.48 (t, J3 = 7.5 Hz, 2H), 2.76 (t, J3 = 7.5 Hz, 2H), 3.21 (m, 
2H), 4.18 (q, J3 = 7.1 Hz, 2H), 4.42 (d, J = 5.7 Hz, 2H), 6.08 (s, 1H), 
6.13 (t, J = 5.3 Hz, 1H), 7.20 – 7.33 (m, 5H). 13C NMR (126 MHz, 
CDCl3): δ (ppm): 14.57, 15.59, 26.73, 35.89, 43.93, 44.42, 59.63, 
127.20, 127.79, 127.89, 128.88, 133.07, 137.86, 153.11, 155.85. 
165.26, 172.61. HR-ESI mass spectrum (MeOH): found 314.17497; 
calcd. for [C19H23NO3+H+] 314.17507. 
 
10a. 9a (50 mg, 0.16 mmol) was dissolved in MeOH (2 ml) in a Anton 
Paar microwave vial (10 ml) equipped with a stirring bar. 1 M NaOH 
(1 ml) was added and the solution was heated to 120 °C for 5 min. 
UPLC measurement showed complete consumption of the starting 
material. The reaction solution was diluted with H2O (5 ml) and 
neutralized to pH = 3 by dropwise addition of 1 M HCl. 10a was 
obtained by evaporating the solvent in vacuo and was used without 
further purification. UPLC (gradient U1): RT = 2.33 min. 
 
11a. The crude of 10a obtained from 9a (36 mg, 0.115 mmol) was 
dissolved in DMF (3 ml).  O-tertbutyl-L-Phenylalanine (33 mg, 0.13 
mmol) and HOBt (17 mg, 0.13 mmol) were added under stirring. After 
5 min, EDC (24 mg, 0.13 mmol) and DIPEA (0.044 ml, 0.25 mmol) 
were added and the solution was stirred for 24 h. The solvent was 
removed in vacuo and the crude was purified by preparative HPLC 
(Method A) and 11a was obtained as a yellow oil (15 mg, 0.03 mmol, 
26 % from 9a). UPLC (gradient U1): RT = 3.19 min. 1H NMR (500 
MHz, CDCl3) δ (ppm) 1.41 (s, 9H), 2.22 (t, J3 = 2.2 Hz, 3H), 2.43 (t, J3 
= 7.6 Hz, 3H), 2.75 (t, J3 = 7.6 Hz, 2H), 3.12 – 3.16 (m, 4H), 4.44 (d, 
J3 = 5.7 Hz, 2H), 4.86 (m, 1H), 5.80 (m, 1H), 5.98 (d, J3 = 7.5 Hz, 1H), 
6.04 (s, 1H), 7.15 – 7.33 (m, 10H). 13C NMR (126 MHz, CDCl3): δ 
(ppm): 15.37, 26.50, 28.13, 35.98, 38.35, 43.83, 53.40, 76.90, 77.16, 
77.41, 82.48, 127.05, 127.73, 127.94, 128.46, 128.60, 128.89, 129.57, 
129.74, 133.12, 136.54, 138.26, 150.68, 151.24, 164.70, 171.23, 
171.79. HR-ESI mass spectrum (MeOH): found 489.27518; calcd. for 
[C30H35N2O4+H+] 489.27478. 
 
8b. 8a (80 mg, 0.34 mmol) was dissolved in DMF (4 ml) in an Anton 
Paar microwave vial (10 ml). Re2(CO)10 (110 mg, 0.17 mmol) was 
added and the mixture was heated by microwave to 220 °C for 15 min 
(Careful, toxic CO gas is released during the reaction, take 
appropriate precautions). UPLC showed complete consumption of the 
starting material. The crude solution was dried in vacuo and used 
without further purification in the next step.  UPLC (gradient UMS1): 
RT = 2.88 min. 
 
9b. 8b (154 mg, 0.31 mmol) was dissolved in DMF (5 ml). 
Benzylamine (0.037 ml, 0.34 mmol) and HOBt (46 mg, 0.34 mmol) 
were added under stirring. After 5 min, EDCI (66 mg, 0.34 mmol) and 
DIPEA (0.120 ml, 0.69 mmol) were added and the solution was stirred 
for 24 h. The solvent was removed in vacuo and the crude was purified 
by preparative HPLC (Method A) and 9b was obtained as an orange 
oil (45 mg, 0.08 mmol, 26%). UPLC (gradient U1): RT = 3.23 min. 1H 
NMR (400 MHz, CDCl3): δ (ppm): 1.31 (t, J3 = 7.1 Hz, 3H), 2.40 (m, 
J = 3.3 Hz, 2H), 2.48 (s, 3H) 2.68 – 2.88 (m, 2H), 4.17 – 4.34 (m, 2H), 
4.45 (d, J = 5.7, 2 H), 5.20 (d, J = 2.1 Hz, 1H), 5.77 (d, J = 2.2 Hz, 1H), 
 
5.85 (t, 1 H), 7.25 – 7.36 (m, 5H). 13C NMR (125 MHz, CDCl3): δ (ppm): 
13.87, 14.28, 23.75, 38.07, 44.10, 61.13, 84.61, 85.73, 86.06, 107.58, 
110.76, 127.95, 128.04, 128.99, 137.78, 164.92, 171.19, 193.56. IR 
bands (Golden Gate, cm-1): 2021, 1918. HR-ESI mass spectrum 
(MeOH): found 584.10780; calcd. for [C22H23O6NRe+H+] 584.10774.  
 
10b. A solution of 9b (43 mg, 0.074 mmol) in MeOH (2 ml) and 1 M 
NaOH (0.15 ml) in a Anton Paar microwave vial (10 ml) was heated 
by microwave to 110 °C for 15 min. The crude was diluted with 1 M 
HCl (10 ml) and washed with DCM twice (2 x 10 ml). The combined 
organic phase was washed once with water (10 ml) dried over MgSO4 
and the solvent removed in vacuo yielding 10b as an orange solid (32 
mg, 0.058 mmol, 78 %). The product was used in the next step without 
further purification. UPLC (gradient U1): RT = 2.81 min. 1H NMR (400 
MHz, CD3OD): δ (ppm): 2.45 (s, 3H), 2.45 (m, 2H), 2.61 – 2.68 (m, 
1H), 2.75 – 2.82 (m, 1H), 4.37 (m, 2H), 5.42 (d, J3 = 2.1 Hz, 1H), 5.89 
(d, J3 = 2.2 Hz, 1H), 7.21 – 7.32 (m, 5H). 13C NMR (101 MHz, CD3OD): 
δ (ppm): 12.63, 23.71, 37.17, 42.77, 84.60, 86.65, 107.46, 110.82, 
126.87, 127.26, 128.18, 138.49, 166.58, 172.44, 193.60. IR bands 
(Golden Gate, cm-1): 2021, 1917. HR-ESI mass spectrum (MeOH): 
found 554.06196; calcd. for [C20H18O6NRe-H+] 554.06189.  
 
11b. 10b (181 mg, 0.326 mmol) was dissolved in DMF (2 ml). O-
tertbutyl-L-Phenylalanine (93 mg, 0.36 mmol) and HOBt (49 mg, 0.36 
mmol) were added under stirring. After 5 min, EDCI (69 mg, 0.36 
mmol) and DIPEA (0.125 ml, 0.72 mmol) were added and the solution 
was stirred for 24 h. The solvent was removed in vacuo and the crude 
was purified by preparative HPLC (Method A) and 11b was obtained 
as a pale red solid and directly used for the next step (112.8 mg, 
0.149 mmol, 46%). UPLC (gradient U1): RT = 3.68 min. 
 
12b. 11b (15 mg, 0.02 mmol) was dissolved in DCM (2 ml) in an Anton 
Paar microwave vial (10 ml). TFA (0.5 ml) was added and the solution 
was heated to 80 °C by microwave for 15 min. The solvent was 
evaporated and the crude was purified by preparative HPLC (Method 
A) and 12b was obtained as an orange oil (15 mg, .0.16 mmol, 80 %). 
UPLC (gradient U1): RT = 3.08 min, 3.13 min. 1H NMR (500 MHz, 
CD3OD): δ (ppm): 2.31 (s, 3 H), 2.37 (s, 3H), 2.42 – 2.45 (m, 4H), 2.61 
– 2.67 (m, 2H), 2.72 – 2.79 (m, 2H), 3.04 – 3.09 (m, 2H), 3.25 – 3.29 
(m, 2H), 4.34 – 4.35 (m, 4H), 4.71 – 4.75 (m, 2H), 5.35 (d, J3 = 2.0 Hz, 
1H), 5.38 (d, J3 = 2.0 Hz, 1H), 5.95 (d, J3 = 2.0 Hz, 1H ), 5.96 (d, J3 = 
2.0 Hz, 1H), 7.16 – 7.32 (m, 20H). 13C NMR (101 MHz, CD3OD): 13.98, 
25.21, 25.25, 37.90, 38.07, 38.62, 38.78, 44.17, 44.19, 55.16, 55.23, 
85.50, 85.65, 86.61, 87.26, 90.94, 91.47, 107.56, 108.37, 110.41, 
110.74, 127.81, 128.27, 128.36, 128.65, 128.67, 129.53, 129.59, 
130.15. 130.25, 138.46, 138.49, 139.84, 165.84, 166.12, 173.85, 
173.88, 174.37, 174.56, 195.12. IR bands (Golden Gate, cm-1): 2021, 
1921. HR-ESI mass spectrum (MeOH): found 725.12675; calcd. for 
[C29H27N2O7Re+Na+] 725.12680.  
 
99mTc experiments. Caution! 99mTc is a γ-emitter (E= 140 keV, t1/2= 
6.02 h) which should only be handled in a licensed and appropriately 
shielded facility. Sodium boranocarbonate releases CO gas, which is 




A Biotage microwave vial (2 – 5 ml) was charged with sodium 
boranocarbonate (4 mg, 38.5 μmol), sodium tartrate dihydrate (7 mg, 
30.4 μmol) and sodium tetraborate decahydrate (7 mg, 18.5 μmol). 
The vial was sealed and flushed with N2 for 5 min before adding 
[99mTcO4]- eluate (1-2 ml) from a commercial generator. The solution 
was heated by microwave to 110 °C for 7 min. In order to normalize 
the overpressure, evolving gases were released with a 1 ml 
disposable syringe. Excess sodium boranocarbonate was quenched 
via dropwise addition of 1 M HCl to pH = 2 and the solution was 
subsequently basified by addition of 1 M NaOH to pH = 8. 
 
General procedure for the labelling of Cp-Ligands 1a, 4a, 6a, 3a 
and 12a. 
Generally, 0.5 ml of a 5 mM stock solution of the respective ligand in 
MeOH was added to a Biotage microwave vial (2 – 5 ml). The vial was 
sealed, and the solvent was removed by passing a stream of N2 
through the vial via two syringe needles for 30 min. 
Method A (1a, 4a, 6a). [99mTc(OH2)3(CO)3]+ (0.5 ml, pH = 8) was added 
to the dried ligand and the pH adjusted to 12 by addition of 1 M NaOH. 
The solution was heated by microwave to 120 °C for 30 min. In order 
to normalize the overpressure, evolving gases were released with a 1 
ml disposable syringe-needle. 
Method B “one pot” (1a, 4a, 6a, 3a, 12a). The vial with the dried ligand 
was opened and sodium boranocarbonate (4 mg, 38.5 μmol), sodium 
tartrate dihydrate (7 mg, 30.4 μmol) and sodium tetraborate 
decahydrate (7 mg, 18.5 μmol). The vial was sealed again and flushed 
with N2 for 5 min before adding [99mTcO4]- eluate (1-2 ml) from a 
commercial generator. The solution was heated by microwave to 
120 °C for 30 min (1a, 4a, 6a) or 140 °C for 30 min (3a) or 2 x 30 min 
(12a). Complexes 2c, 5c, 7c and 3c were obtained in radiochemical 
puritiy > 95%. For 12c, some [99mTcO4]- and [99mTc(OH2)3(CO)3]+  was 
observed (< 20 %, c.f. Figure SI89). 12c was purified by loading the 
reaction mixture onto a Chromafix C18 cartridge and washing it with 
H2O (2 ml). Pure 12c could be eluted by washing the cartridge with 
MeOH (2 ml). 
 
X-ray Crystallography. Crystallographic data were collected at 
183(2) K with Mo Kα radiation (λ = 0.7107 Å) that was graphite-
monochromated on an Oxford Diffraction CCD Xcalibur system with a 
Ruby detector. Suitable crystals were covered with oil (Infineum 
V8512, formerly known as Paratone N), placed on a nylon loop that is 
mounted in a CrystalCap Magnetic™ (Hampton Research) and 
immediately transferred to the diffractometer. The program suite 
CrysAlisPro was used for data collection, multi-scan absorption 
correction and data reduction.[22] The structures were solved with 
direct methods using SIR97[23] and were refined by full-matrix least-
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Multifunctional cyclopentadiene ligands with tuneable properties and their rhenium 
and 99mTc complexes were prepared following a versatile synthetic route. 
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